MedTrace Logo

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

NCT06244485 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-02-04

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

Valemetostat tosylate

Administered orally once daily

DRUG

T-DXd

One IV infusion Q3W on Day 1 of each 21-day cycle

DRUG

Dato-DXd

One IV infusion Q3W on Day 1 of each 21-day cycle.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-16
Primary Completion
2028-11-01
Completion
2028-11-01
FDA Drug
Yes

Countries

  • United States
  • China
  • Italy
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06244485 on ClinicalTrials.gov